Pfizer Inc. has announced positive topline results from the Phase 3 BASIS study evaluating HYMPAVZI™ (marstacimab) for adults and adolescents with hemophilia A or B with inhibitors. The study demonstrated a statistically significant and clinically meaningful reduction in annualized bleeding rate compared to on-demand treatment in patients aged 12 and older. HYMPAVZI, administered as a once-weekly subcutaneous injection, showed a generally well-tolerated safety profile. Results from the full Phase 3 dataset are currently being analyzed, with additional data to be presented at upcoming medical meetings. Pfizer intends to discuss these findings with regulatory authorities to initiate filings for HYMPAVZI's approval for use in patients with hemophilia with inhibitors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.